IDEXX LABORATORIES INC /DE Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
IDEXX LABORATORIES INC /DE (IDXX) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $9.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-20
- IDEXX LABORATORIES INC /DE unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $9.01M, a 1228.61% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $678.00K, a 91.00% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $7.54M, a 388.02% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $1.54M, a 187.52% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|
| 2025-12-31 | $9.01M 10-K · filed 2026-02-20 |
| 2024-12-31 | $678.00K 10-K · filed 2026-02-20 |
| 2023-12-31 | $7.54M 10-K · filed 2026-02-20 |
| 2022-12-31 | $1.54M 10-K · filed 2025-02-21 |
| 2021-12-31 | $537.00K 10-K · filed 2024-02-22 |
| 2020-12-31 | $6.45M 10-K · filed 2023-02-16 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-16 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-12 |
| 2017-12-31 | $713.00K 10-K · filed 2020-02-14 |
| 2016-12-31 | $1.33M 10-K · filed 2019-02-15 |
| 2014-12-31 | $2.24M 10-K · filed 2017-02-17 |
| 2013-12-31 | $317.00K 10-K · filed 2016-02-17 |
| 2009-12-31 | $513.00K 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |